Efficacy and Safety of Tezepelumab in Patients with Eosinophilic Esophagitis
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) - CROSSING A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of ...
Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eosinophilic infiltration of the esophagus MedDRA version: 20.1;Level: LLT;Classification code 10064220;Term: Eosinophilic esophagitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune respo ...
Product Name: Tezepelumab via APFS Product Code: MEDI9929 anti-TSLP mAb (AMG157) INN or Proposed INN: Tezepelumab Other descriptive name: AMG 157 Product Name: Tezepelumabvia APFS Product Code: MEDI9929 anti-TSLP mAb (AMG157) INN or Proposed INN: T ...
AstraZeneca AB
NULL
Authorised-recruitment may be ongoing or finished
Female: yes Male: yes
360
Phase 3
United States;Czechia;Slovakia;Greece;Finland;Spain;Austria;Israel;Italy;Canada;Belgium;Brazil;Denmark;Australia;Norway;Germany;Netherlands;China;Japan;New Zealand;Sweden United States;Czechia;Slovakia;Greece;Finland;Spain;Austria;Israel;Italy;Canada;Belgium;Brazil;Denma ...
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients With Eosinophilic Esophagitis (CROSSING). A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of ...
Eosinophilic Esophagitis
Biological: Tezepelumab;Other: Placebo
AstraZeneca
Amgen
Recruiting
12 Years
80 Years
All
360
Phase 3
United States;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden United States;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;Finland;Germany;Greece;I ...